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org/licenses/by-nc-nd/4.0/).Abstract Background: Methylenetetrahydrofolate dehydrogenase (MTHFD1) catalyzes three
sequential reactions that metabolize derivatives of tetrahydrofolate (THF) in folate-dependent
one-carbon metabolism. Impaired MTHFD1 ﬂux has been linked to disturbed lipid metabolism
and oxidative stress. However, limited information is available on its relation to the development
of atherothrombotic cardiovascular disease.
Methods and results: We explored the association between a MTHFD1 polymorphism (rs1076991
C > T ) and acute myocardial infarction (AMI), and potential effect modiﬁcations by folic acid/B12
and/or vitamin B6 treatment in suspected stable angina pectoris patients (n Z 2381) partici-
pating in the randomized Western Norway B Vitamin Intervention Trial (WENBIT). During the
median follow-up of 4.9 years 204 participants (8.6%) suffered an AMI. After adjusting for estab-
lished CVD risk factors, the MTHFD1 polymorphism was signiﬁcantly associated with AMI (HR:
1.49; 95% CI, 1.23e1.81). A similar association was observed among patients allocated to treat-
ment with vitamin B6 alone (HR: 1.53; 95% CI, 1.01e2.31), and an even stronger relationship
was seen in patients treated with both vitamin B6 and folic acid/B12 (HR: 2.35; 95% CI, 1.55
e3.57). However, no risk association between the MTHFD1 polymorphism and AMI was seen
in patients treated with placebo (HR: 1.29; 95% CI, 0.86e1.93) or folic acid/B12 (1.17; 95% CI,
0.83e1.65).
Conclusion: A common and functional MTHFD1 polymorphism is associated with increased risk
of AMI, although the risk seems to be dependent on speciﬁc B vitamin treatment. Further studies
are warranted to elucidate the possible mechanisms, also in order to explore potential effect
modiﬁcations by nutritional factors.
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Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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The role of one-carbon metabolism (OCM) in the patho-
genesis of atherothrombotic cardiovascular disease (CVD)
is not fully understood. Observational studies have shown
that elevated plasma homocysteine is associated with
increased CVD risk [1], whereas plasma pyridoxal 50-
phosphate (PLP) is inversely related with CVD indepen-
dent from plasma homocysteine [2]. Although folic acid
therapy has been suggested to signiﬁcantly reduce the risk
of ﬁrst stroke in adults with hypertension [3], several
randomized clinical trials aimed for secondary prevention
have failed to reduce CVD risk by treatment with
homocysteine-lowering folic acid/B12 or by vitamin B6
[4,5]. Thus, the underlying mechanisms for the observed
associations in prospective studies are largely unknown.
The highly interconnected network of one-carbon meta-
bolism makes it difﬁcult using classical observational ap-
proaches to delineate pathways associated with
pathogenesis and the responsible factors. However, ge-
netic variation with implications on certain metabolic
pathways may serve as a more robust proxy for life-time
susceptibility to a certain disorder which may allow
causal inference [6].
Associations between CVD risk factors and several ge-
netic variants of OCM have been widely researched [7], but
few studies have focused on relationships with the cyto-
solic methylenetetrahydrofolate dehydrogenase
(MTHFD1). MTHFD1 catalyzes three sequential reactions
involved in the interconversion of one-carbon derivatives
of tetrahydrofolate (THF, Fig. 1) [8]. A common single
nucleotide polymorphism (SNP) MTHFD1 105C > TFigure 1 The roles of MTHFD1 enzyme in the folate-mediated one carbon m
(C1-THF) metabolizing enzyme that plays an important role in the folate
involved in DNA synthesis, as well as homocysteine remethylation. B vitam
maintain and modulate the normal functionalities of one carbon metaboli
DMG, dimethylglycine; MTHFD1, methylenetetrahydrofolate dehydrog
methyltetrahydrofolate-homocysteine methyltransferase; SAH, S-adenosy
serine hydroxymethyltransferase.(rs1076991) is located in its promoter region, with a re-
ported minor allele frequency (MAF) of 49% [9]. The minor
T-allele has been associated with an approximately 62.5%
drop in transcription rate of the MTHFD1 enzyme due to
decreased promoter activity [10]. Therefore, this SNP may
adequately represent MTHFD1 deﬁciency. Impaired
MTHFD1 ﬂux has been suggested to disturb lipid meta-
bolism in mice by alternating hepatic choline, betaine and
dimethylglycine (DMG) concentrations [11] as well as
interrupting intercellular NADPH production [12].
Genome-wide association studies (GWAS) additionally
found variations in MTHFD1L, the mono-functional coun-
terpart to MTHFD1 in the mitochondria, to be associated
with risk of early-onset acute myocardial infarction (AMI)
[13]. Hence, genetic variation in MTHFD1 may potentially
be associated with CVD risk.
B vitamin status can inﬂuence OCM, but it likely de-
pends on the genetic background among individuals [14],
reﬂecting geneeenvironment interactions. Among partic-
ipants of the Western Norway B Vitamin Intervention Trial
(WENBIT), we therefore performed a candidate gene
analysis of MTHFD1 rs1076991 for its association with AMI,
and further focusing on potential interactions with allo-
cation into B vitamin treatments.Methods
Study design and population
The WENBIT (ClinicalTrials.gov number NCT00354081)
was carried out to investigate the effect of B vitaminetabolism in cytoplasm. MTHFD1 is a trifunctional C1 tetrahydrofolate
metabolism. Those THF derivatives catalyzed by MTHFD1 are closely
ins (B2, B6, folic acid and B12) are crucial sources of coenzymes that
sm. Abbreviations: DHF, dihydrofolate; DHFR, dihydrofolate reductase;
enase 1; MTHFR, methylenetetrahydrofolate reductase; MTR, 5-
lhomocysteine; SAM, S-adenosylmethionine; Sarc, sarcosine; SHMT,
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and mortality [4]. In speciﬁc, WENBIT had a 2  2 factorial
design in which participants with suspected or veriﬁed
coronary artery disease (CAD), or aortic stenosis, were
randomized to receive a daily capsule containing one of
the following: 1) folic acid 0.8 mg plus vitamin B12
(cyanocobalamin) 0.4 mg plus vitamin B6 (pyridoxine
hydrochloride) 40 mg; 2) folic acid plus vitamin B12; 3)
vitamin B6; 4) placebo. In total, there were 3090 patients
enrolled in WENBIT study. Among them, 2584 patients
underwent coronary angiography for stable angina pec-
toris (SAP), 461 for acute coronary syndromes (ACS) and 45
for aortic valve stenosis at Haukeland University Hospital,
Bergen, Norway or Stavanger University Hospital, Sta-
vanger, Norway. The current study included patients with
SAP only. Participants without successful genotyping
(n Z 203) were excluded, leaving a total of 2381 partici-
pants for the ﬁnal analyses.
The study protocol was in accordance with the princi-
ples of the Declaration of Helsinki, and was approved by
the Regional Committees for Medical and Health Research
Ethics, the Norwegian Medicines Agency and the Norwe-
gian Data Inspectorate. All subjects were informed and
agreed to participate in extended follow-up including ge-
netic studies.
Baseline data
Smoking status and the extent of CAD at angiography were
deﬁned as previously described [15]. Obesity was deﬁned
as body mass index (BMI)  30 kg/m2. Diabetes mellitus
was classiﬁed by self-reports or by glucose criteria (fasting
plasma glucose  7.0 mmol/L; or random plasma
glucose  11.1 mmol/L measured at baseline of the study).
Follow-up and clinical endpoints
The primary outcome for the present study was fatal or
non-fatal AMI. Study subjects were followed from enroll-
ment until the onset of AMI, or until the end of 2006.
Details on the collection and classiﬁcation of clinical end-
points have been described previously [16].
Genotyping and biochemical analysis
Clinical information and blood samples were obtained at
baseline before or immediately after coronary angiography
and the blood samples were stored at 80 C. Earlier re-
ports have described the biochemical analyses for relevant
clinical indices [15,16]. Besides, genotyping of MTHFD1
rs1076991 polymorphism was performed by MALDI-TOF
mass spectrometry [17].
Statistical analysis
Baseline categorical variables were summarized as per-
centages and continuous variables were presented as
medians (interquartile range (IQR)). Hardy-Weinberg
equilibrium (HWE) and MAF of MTHFD1 rs1076991polymorphism were also calculated. Baseline variables
across MTHFD1 rs1076991 genotypes (CC, CT and TT) were
assessed by un-adjusted median linear regression for
continuous and logistic regression or KruskaleWallis rank
sum test for categorical variables.
The risk association between the MTHFD1 poly-
morphism and AMI was tested in two Cox regression
models: A simple model was adjusted for age (continuous)
and gender (male/female); a multivariate model was
further adjusted for established CAD risk factors including
smoking status (yes/no), obesity (yes/no), hypertension
(yes/no) and diabetes mellitus (yes/no). Additional ad-
justments for baseline serum apoA-1, apoB, and angio-
graphic signs of coronary artery disease (CAD) had minor
inﬂuences on the estimates and were therefore not
included in the models. An additive genetic model was
used in all survival analyses, in which we assumed a linear
risk relationship among MTHFD1 rs1076991 CC, CT, TT
genotypes. This is equivalent to a comparison of the T-
allele versus the C-allele. Proportional hazards assump-
tions were examined using the Schoenfeld and scaled
Schoenfeld residuals. Interactions between vitamin B
treatments and the MTHFD1 polymorphism on the
outcome were evaluated by adding interaction product
terms in the multivariate Cox models.
The statistical analyses were performed in R (R version:
3.1.0) using packages “genetics” and “survival” [18]. All
reported P values were two-sided, and P < 0.05 was
considered statistically signiﬁcant.Results
Baseline characteristics
Of the 2381 SAP participants included, 1888 (79.3%) were
males. The median (IQR) age of the population was 62
(48e76) years. Most baseline characteristics in the study
did not differ according to the MTHFD1 rs1076991 geno-
types (P  0.08, Table 1). However, diabetes mellitus was
inversely associated with the number of T-allele
(P Z 0.02). We did not observe any association between
biomarkers for OCM and the MTHFD1 polymorphism at
baseline (P  0.25). The observed MAF of the MTHFD1
polymorphism was 42.7% and did not deviate from Hardy-
Weinberg equilibrium (P Z 0.31).The MTHFD1 polymorphism and AMI risk
During a median (IQR) follow-up time of 4.9 (2.8e7.0)
years, 204 participants (8.6%) suffered an AMI.
KaplaneMeier curves showed a signiﬁcant association
between the MTHFD1 polymorphism and AMI occurrence
(Plog-rankZ 3.5  104) (Fig. 2). After adjusting for age and
gender, the minor T-allele was linearly associated with
AMI (HR: 1.46; 95% CI, 1.20e1.76), which remained sig-
niﬁcant after multivariate adjustment (HR: 1.49; 95% CI,
1.23e1.81). Notably, similar results were also observed in
the complete WENBIT population (data not shown).
Table 1 Baseline characteristics of the WENBIT cohort according to the MTHFD1 promoter polymorphism.
CC CT TT Total P for trend
(N Z 794) (N Z 1141) (N Z 446) (N Z 2381)
General characteristics
Age (year) 62  14 62  14 62  15 62  14 0.71
Gender (male, %) 626 (79) 909 (80) 353 (79) 1888 (79) 0.83
Body mass index (kg/m2) 26.6  4.6 26.4  4.6 26.4  4.6 26.5  4.6 0.16
Cardiovascular history and risk factors, n (%)
Prior MI 346 (43.6) 521 (45.7) 194 (43.5) 1061 (44.5) 0.86
Prior PCI 167 (21.0) 255 (22.3) 99 (22.2) 521 (21.9) 0.57
Prior CABG 105 (13.2) 165 (14.5) 60 (13.5) 330 (13.9) 0.79
Hypertension 390 (49.1) 533 (46.7) 203 (45.6) 1126 (47.3) 0.19
Diabetes mellitus 132 (16.6) 162 (14.2) 52 (11.7) 346 (14.5) 0.02
Current smoking 209 (26.3) 357 (31.3) 133 (29.8) 699 (29.4) 0.08
Angiographic evidence of CAD 0.80
No signiﬁcant CAD 87 (11.0) 133 (11.7) 48 (10.8) 268 (11.3)
Single vessel disease 234 (29.5) 309 (27.1) 127 (28.5) 670 (28.1)
Double vessel disease 210 (26.4) 297 (26.0) 127 (28.5) 634 (26.6)
Triple vessel disease 263 (33.1) 402 (35.2) 144 (32.2) 263 (34.0)
Biochemistry parameters
ApoB/ApoA1 ratio 0.7 (0.3) 0.7 (0.3) 0.7 (0.3) 0.7 (0.3) 0.60
Estimated GFR (mL/min/1.73 m2) 92 (17) 92 (19) 92 (20) 92 (18) 0.42
Serum CRP (mg/L) 1.8 (2.9) 1.7 (2.5) 1.9 (2.7) 1.8 (2.7) 0.74
Serum Creatinine (mmol/L) 90 (16) 91 (17) 90 (17) 90 (17) 0.18
Treatment following baseline coronary angiography, n (%) 0.62
No or medications only 275 (34.6) 378 (33.1) 163 (36.5) 816 (34.3)
Percutaneous coronary intervention 300 (37.8) 462 (40.5) 169 (37.9) 931 (39.1)
Coronary artery bypass grafting 193 (24.3) 265 (23.2) 101 (22.6) 559 (23.5)
Medication at discharge, n (%)
Aspirin 713 (89.8) 1024 (89.7) 407 (91.3) 2144 (90.0) 0.48
Statins 706 (89.0) 1009 (88.4) 392 (87.9) 2107 (88.5) 0.58
Beta blockers 614 (77.3) 884 (77.5) 358 (80.2) 1856 (78.0) 0.64
ACEIs 178 (22.4) 224 (19.6) 96 (21.5) 498 (20.9) 0.51
Loop diuretics 87 (11.0) 110 (9.6) 40 (9.0) 233 (9.8) 0.23
Biomarkers for OCM
Plasma homocysteine (mmol/L) 10.2 (3.5) 10.2 (3.7) 10.4 (3.6) 10.2 (3.6) 0.76
Plasma PLP (nmol//L) 40.4 (27.2) 39.0 (26.1) 40.5 (27.5) 40.0 (26.9) 0.89
Serum folate (nmol//L) 9.8 (7.4) 9.9 (7.0) 10.0 (7.4) 9.9 (7.2) 0.24
Serum cobalamin (mmol/L) 331 (160) 341 (173) 333 (172) 337 (170) 0.79
Serum MMA (mmol/L) 0.16 (0.06) 0.16 (0.07) 0.16 (0.07) 0.16 (0.07) 0.25
Abbreviations: ACEI, angiotensin-converting-enzyme inhibitor; Apo, apolipoprotein; CABG, coronary artery bypass grafting; CAD, coronary artery
disease; CRP, C-reactive protein; GFR, glomerular ﬁltration rate; MMA, methylmalonic acid; OCM, one carbon metabolism; PCI, percutaneous
coronary intervention; PLP, pyridoxal phosphate.
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Table 2 describes the risk associations between the
MTHFD1 rs1076991 and AMI according to WENBIT treat-
ment allocation. Among patients treated with placebo or
folic acid/vitamin B12, we found similar trends towards
positive associations between the number of T-allele and
AMI risk in the multivariate models (HR: 1.29; 95% CI,
0.86e1.93 and 1.17; 95% CI, 0.83e1.65, respectively;
PintZ 0.76). A signiﬁcant association was observed among
patients allocated to vitamin B6 treatment (HR: 1.53; 95%CI, 1.01e2.31), which, however, was not statistically
different from placebo treatment (PintZ 0.59). Notably, we
observed a more profound association between the poly-
morphism and AMI among patients allocated to the com-
bined vitamin B6 and folic acid/B12 treatment (HR: 2.35;
95% CI, 1.55e3.57; Pint Z 0.047 vs. placebo). This interac-
tion seemed to be introduced by a shift from a lower to
higher risk of the combined B vitamin treatment according
to the number of T-allele (HR among the CC homozygotes:
0.38; 95% CI, 0.12e1.23; CT heterozygotes: 1.14; 95% CI,
0.68e1.93; and TT homozygotes: 1.98; 95% CI, 0.86e4.55).
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Main ﬁndings
A common and functional MTHFD1 polymorphism is
associated with increased risk of AMI among the SAP pa-
tients in WENBIT. We furthermore observed a signiﬁcant
interaction between combined treatment of folic acid/
vitamin B12 and vitamin B6 with the MTHFD1 poly-
morphism on risk of AMI occurrence.Strengths and limitations
The MTHFD1 rs1076991 is a common polymorphism,
which ensures sufﬁcient power to detect underlying gen-
eedisease associations. The large sample size and long-
term follow-up are strengths of the current study. To
decrease the probability of type I errors by multiple
testing, we did not assess the existence of other genetic
variants besides the prime candidate SNP in the region of
linkage disequilibrium (LD) at the MTHFD1 locus. Based on
HapMap data, several SNPs in this region are in strong LD
with MTHFD1 rs1076991 and may therefore represent the
underlying causes of the observed association
(Supplementary table 1 and ﬁgure 1). Also, our results
should be validated in independent populations, prefer-
ably with other clinical and baseline characteristics than
the present cohort.
In the current investigation, we excluded patients with
an acute coronary syndrome to avoid the inﬂuence of
acute inﬂammation on SNPetreatment interactions.
Notably, several previous studies have shown that acute
coronary syndrome is associated with inﬂammatoryFigure 2 KaplaneMeier estimates of AMI according to the MTHFD1
polymorphism.response [19], which affects biomarkers of B vitamin status
[20]. Thus, the current results are primarily relevant for
patients with SAP only.
The cytosolic MTHFD1, diseases and biomarkers
Production of cytosolic C1-THF synthase (10-formyl-THF,
5,10-methenyl-THF and 5,10 methylene-THF) are involved
in de novo purine and thymidylate synthesis, as well as in
homocysteine remethylation. However, we did not observe
any association of the MTHFD1 rs1076991 polymorphism
with plasma homocysteine levels, which concurs with
results from another study [21]. Population studies have
shown associations between MTHFD1 polymorphisms and
neural tube defects [22] and gastric cancer [23]. One study
showed strong association between MTHFD1 rs1076991
and B-cell acute lymphoblastic leukemia [24]. To the best
of our knowledge, the current study is among the ﬁrst to
focus on the promoter polymorphism of MTHFD1 with
AMI occurrence in SAP patients.
Effects of B vitamin treatments on the association of
MTHFD1 with AMI
We found a particularly strong association between the
MTHFD1 polymorphism and AMI in patients allocated to
combined vitamin B6 and folic acid/B12 treatment.
Concomitant high levels of folate and B6 resulted in a
non-signiﬁcant beneﬁcial effect against AMI in the
MTHFD1 CC homozygous, and showed a more adverse
tendency in patients with MTHFD1 T-allele. Vitamin B6
intake is shown to be inversely related to hepatic and
plasma glycine levels [25], and positively associated with
adenosylmethionine (SAM) [26] due to decreased SAM
consumption by GNMT. Accumulated SAM has been
shown to cause hepatic lipid accumulation and other
atherothrombotic changes, including overt dyslipidemia
[27] and oxLDL-induced foam cell formation [28]. On the
other hand, adequate folate status is crucial for balancing
the transmethylation ﬂux. Folate deﬁciency has been
associated with elevated circulating formate levels,
impaired nucleotide synthesis, DNA hypomethylation and
hyperhomocysteinemia [29]. Recent evidence linked folate
intake with elevated hepatic SAM [30], which is a known
inhibitor to betaineehomocysteine methlytransferase
[31], which is suggested to regulate liver lipids and to
induce apoB expression [32]. Indeed, excess SAM has been
associated with hepatic apoB mRNA expression and VLDL
assembly [33]. Coupled with the evidence that MTHFD1
deﬁciency has also been associated with accumulated
intercellular SAM [34], these ﬁndings may be indicative of
a potential mechanism in which lipid accumulation is
exacerbated by the combined treatment in those with
MTHFD1 deﬁciency, which may further promote athero-
sclerosis. Nevertheless, the interaction of the MTHFD1
genotype with glycine, lipid and B6 metabolism should be
further explored.
Genetic analysis may provide more insights to the un-
derlying pathophysiology of atherosclerosis. The
Table 2 HRs of AMI by MTHFD1 rs1076991 polymorphism in WENBIT population and different treatment arms.
Events/total Simple modela Multivariate modelb Pintc
HR 95% CI P value HR 95% CI P value
WENBIT 204/2381 1.46 1.20e1.76 1.3  104 1.49 1.23e1.81 5.5  105
Placebo 48/601 1.27 0.85e1.90 0.24 1.29 0.86e1.93 0.22 Ref.
Vitamin B6 46/593 1.44 0.95e2.16 0.08 1.53 1.01e2.31 0.04 0.59
Folic acid/B12 61/598 1.19 0.85e1.67 0.31 1.17 0.83e1.65 0.38 0.76
B6 þ Folic acid/B12 49/589 2.28 1.51e3.44 9.0  105 2.35 1.55e3.57 6.3  105 0.047
a Simple model was adjusted for age and gender.
b Multivariate model was adjusted further for smoking status, obesity, hypertension and diabetes mellitus.
c Pint refers to the gene-treatment interaction in multivariate models which compared SNP association between placebo group and designated
treatment groups.
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morphism through allocation to vitamin B6 and folic acid/
B12 in the current study may be interpreted in the context
of personalized medicine. Since B-vitamin status may be
correlated to other lifestyle factors like obesity or the
intake of macronutrients, further studies are warranted to
examine if the MTHFD1 genotype may inﬂuence the as-
sociation between such lifestyle factors and atherogenesis,
and if such association may be mediated partly by vitamin
status.Conclusion
We demonstrate that B vitamin treatment may introduce a
strong association between a common and functional
MTHFD1 promoter polymorphism and AMI risk in patients
with SAP. Our results may potentially provide insight into
the conﬂicting results of randomized B vitamin interven-
tion trials on cardiovascular disease. Further studies
should evaluate if this genotype may modify the risk of
chronic diseases affected by other dietary or lifestyle
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